The Gene-to-Patient Market Size is valued at USD 134.6 billion in 2023 and is predicted to reach USD 341.4 billion by the year 2031 at a 12.5% CAGR during the forecast period for 2024-2031.
The gene-to-patient method intends to diagnose, treat, or prevent genetic diseases by creating and administering gene therapies that correct genetic information within a patient's cells. Beginning with the creation of gene therapy and continuing through its clinical use and patient care, this encompasses the whole process. The gene-to-patient market is driven by progress in genetic research and biotechnological innovations.
Additionally, the trend is sped up even more by a rising desire for personalized medicine, higher healthcare costs, and more people with chronic diseases. Gene-to-patient is also being supported by regulatory frameworks that are friendly and clinical studies that are growing, which is driving market growth. Moreover, the market's growth in developing countries will also be affected by the increasing concern for the accessibility and cost of healthcare around the world. The gene-to-patient business has great potential for future growth as the sector adjusts to new regulations and creates ground-breaking solutions.
However, the market growth is hampered by the strict regulatory criteria of gene-to-patient, lack of awareness, and high cost of treatment. In addition, the gene-to-patient business was greatly affected by the COVID-19 pandemic, which sped up the development of genetic technologies and vaccine research. Quick progress and partnerships in the field of genetic disorders were made possible by enhanced financing and regulatory flexibility. Furthermore, factors driving market expansion include an uptick in genetics disorders cases and a surge in research and development efforts related to the creation of these medications. Gene-to-patient therapy is in high demand because the incidence of long-term problems is on the rise worldwide.
The gene-to-patient market is segmented based on type, application, end-user, technology, and distribution channel. Based on type, the market is segmented into gene therapy, gene editing, and gene silencing. By application, the market is divided into cancer treatment, genetic disorders, cardiovascular diseases, rare diseases, and infectious diseases. The end user market is categorized into hospitals, research institutes, biopharmaceutical companies, and diagnostic laboratories. By technology, the market is segmented into CRISPR, viral vector technology, non-viral delivery technology, and antisense oligonucleotide technology. The distribution channel segment includes direct sales, online sales, and third-party distributors.
The gene therapy gene-to-patient market is expected to lead with a major market share because biotechnology and genetic engineering have come a long way, greatly improving the effectiveness of treatments for genetic illnesses. Additionally, important factors propelling the market forward include an uptick in gene therapy awareness among patients, an increase in healthcare R&D spending, the frequency of chronic diseases, and the number of regulatory approvals for the treatment. Partnerships between biotech and pharmaceutical businesses to create new treatments are fueling this industry's expansion.
Hospitals are growing rapidly in the gene-to-patient market because they are becoming more reliant on cutting-edge gene therapies to cure intricate gene diseases. Additionally, government financing for the integration of state-of-the-art medical technology, partnerships with biotech companies for clinical studies, and improved infrastructure to support specialized gene therapies are driving this increase. In addition, personalized medicine is becoming increasingly popular among patients, and hospitals are responding by providing more tailored and effective treatment alternatives.
The North American gene-to-patient market is projected to have the largest market revenue share in the foreseeable future. It can be attributed to the high frequency of genetic problems, a well-developed healthcare system, substantial funding for biotechnology research and development, and enabling regulatory regulations. This region's emphasis on cutting-edge, individualized healthcare is a key factor in its growing market growth. In addition, Europe is estimated to grow rapidly in the global gene-to-patient market due to the region's huge population, rising need for quality healthcare, and the rise in health awareness among the populace. Rising efforts by the government to promote innovative medicines and in need of cutting-edge healthcare technology.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 134.6 Bn |
|
Revenue Forecast In 2031 |
USD 341.4 Bn |
|
Growth Rate CAGR |
CAGR of 12.5% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type, Application, End-User, Technology, And Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Illumina, Thermo Fisher Scientific, Roche Diagnostics, Qiagen, BioRad Laboratories, Abbott Laboratories, PerkinElmer, Invitae, Myriad Genetics, Guardant Health, Foundation Medicine, Genomic Health, Agilent Technologies, Laboratory Corporation of America (LabCorp), Exact Sciences and Other Market Players |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Gene-to-Patient Market Snapshot
Chapter 4. Global Gene-to-Patient Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Gene-to-Patient Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Gene-to-Patient Industry Trends
Chapter 5. Gene-to-Patient Market Segmentation 1: By Application, Estimates & Trend Analysis
5.1. Market Share by Application, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
5.2.1. Cancer Treatment
5.2.2. Genetic Disorders
5.2.3. Cardiovascular Diseases
5.2.4. Rare Diseases
5.2.5. Infectious Diseases
Chapter 6. Gene-to-Patient Market Segmentation 2: By End-User, Estimates & Trend Analysis
6.1. Market Share by End-User, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-User:
6.2.1. Hospitals
6.2.2. Research Institutes
6.2.3. Biopharmaceutical Companies
6.2.4. Diagnostic Laboratories
Chapter 7. Gene-to-Patient Market Segmentation 3: By Technology, Estimates & Trend Analysis
7.1. Market Share by Technology, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Technologys:
7.2.1. CRISPR
7.2.2. Viral Vector Technology
7.2.3. Non-Viral Delivery Technology
7.2.4. Antisense Oligonucleotide Technology
Chapter 8. Gene-to-Patient Market Segmentation 4: By Type, Estimates & Trend Analysis
8.1. Market Share by Type, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Types:
8.2.1. Gene Therapy
8.2.2. Gene Editing
8.2.3. Gene Silencing
Chapter 9. Gene-to-Patient Market Segmentation 5: By Distribution Channel, Estimates & Trend Analysis
9.1. Market Share by Distribution Channel, 2023 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Distribution Channeles:
9.2.1. Direct Sales
9.2.2. Online Sales
9.2.3. Third-party Distributors
Chapter 10. Gene-to-Patient Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Gene-to-Patient Market, Regional Snapshot 2023 & 2031
10.2. North America
10.2.1. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.2.3. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.2.4. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.2.5. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.2.6. North America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.3. Europe
10.3.1. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.3.3. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.3.4. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.3.5. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.3.6. Europe Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.4. Asia Pacific
10.4.1. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024- 2031
10.4.3. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.4.4. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts By Technology, 2024-2031
10.4.5. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.4.6. Asia Pacific Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts By Distribution Channel, 2024-2031
10.5. Latin America
10.5.1. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.5.3. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.5.4. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.5.5. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.5.6. Latin America Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
10.6. Middle East & Africa
10.6.1. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
10.6.3. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
10.6.4. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2024-2031
10.6.5. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Type, 2024-2031
10.6.6. Middle East & Africa Gene-to-Patient Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2024-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Illumina
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Offerings
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Thermo Fisher Scientific
11.2.3. Roche Diagnostics
11.2.4. Qiagen
11.2.5. BioRad Laboratories
11.2.6. Abbott Laboratories
11.2.7. PerkinElmer
11.2.8. Invitae
11.2.9. Myriad Genetics
11.2.10. Guardant Health
11.2.11. Foundation Medicine
11.2.12. Genomic Health
11.2.13. Agilent Technologies
11.2.14. Laboratory Corporation of America (LabCorp)
11.2.15. Exact Sciences
11.2.16. Genscript Biotech Corporation
11.2.17. CRISPR Therapeutics AG
11.2.18. Editas Medicine
11.2.19. Intellia Therapeutics Inc.
11.2.20. Beam Therapeutics Inc.
11.2.21. Caribou Biosciences Inc.
11.2.22. Lonza Group Ltd.
11.2.23. Other Market Players
Gene-to-Patient Market By Type-
Gene-to-Patient Market By Application-
Gene-to-Patient Market By End-user-
Gene-to-Patient Market By Technology-
Gene-to-Patient Market By Distribution Channel-
Gene-to-Patient Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
